30 closest matches · ranked by relevance
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Overall Objective Response — 3; 29; 39 participants
Metastatic Transitional Cell Cancer of the Urothelial Tract
Primary: Response Rate — 11 percentage of participants
Transitional Cell Carcinoma
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Urinary Bladder Neoplasms
Primary: Number of Participants With Freedom From Progression of Cancer at 4 Months — 20 Participants
Bladder Cancer
Primary: Progression Free Survival — 8.2 months
Metastatic Transitional Cell Carcinoma of the Urothelium
Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS
Transitional Cell Carcinoma · Bladder Cancer
Primary: Median Progression-Free Survival (PFS) — 2.56; 1.58 months — p=0.939
Bladder Cancer · Metastatic Transitional Cell Carcinoma
Primary: Number of Participants Who Were Progression Free at 2 Months — 23; 22 Participants
Bladder Cancer Cell Transitional · Non-Muscle Invasive Bladder Cancer · Bladder Cancer
Primary: Part 1: Maximum Tolerated Dose or Maximum Deliverable Dose (MDD) — NA; 360 mg
Carcinoma of Urinary Tract · Urethral Carcinoma · Carcinoma of Ureter
Primary: Progression-Free Survival (PFS) — 2.8; 5.4; 1.6 months
Urothelial Carcinoma · Ureteral Neoplasms · Ureter Cancer
Primary: Progression Free Survival — 1.9 Months
Infiltrating Bladder Urothelial Carcinoma
Primary: Overall Pathological Response Rate — 57.7 % of participants
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Transitional Cell Carcinoma of the Bladder
Primary: Feasibility — 8; 15 participants
Non-Transitional Cell Carcinoma of the Urothelial Tract · Small Cell of the Bladder · Adenocarcinoma of the Bladder
Primary: Overall Response Rate — 2; 11; 2 Participants
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants
Bladder Cancer
Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants
Distal Urethral Cancer · Proximal Urethral Cancer · Recurrent Bladder Cancer
Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants
Bladder Cancer
Primary: Complete Response Rate at 3 Months — 39 percentage of participants
Adenocarcinoma of the Bladder · Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Tumor Response Rate — 4.5 percentage of responders
Bladder Cancer
Primary: Progression Free Survival (PFS) — 9.5 months
Transitional Cell Carcinoma of Bladder · Superficial Bladder Cancer
Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)
Bladder Cancer
Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Carcinoma, Transitional Cell · Bladder Cancer · Bladder Neoplasm
Primary: Objective Response Rate (ORR) — 1 participants
Myeloproliferative Disorder · Urothelial Carcinoma · Cancer
Primary: Evaluate the Time to Disease Progression — 6.5; 13.9 months
Urothelial Carcinoma
Primary: Objective Response Rate — 8.3 Percentage of participants
Metastatic Renal Cell Carcinoma
Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants
Renal Cell Carcinoma
Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants